I would like to thank Takashi Miyachi and colleagues for their Correspondence regarding the RESMAIN trial. The most prevalent forms of cutaneous T-cell lymphoma are mycosis fungoides and its variants, as well as Sézary syndrome.
According to the current guidelines, in the early stages of the disease, the recommended therapeutic approach is based on skin-directed therapies. In more advanced stages of the disease, the recommended treatment involves primarily non-toxic systemic drugs, such as pegylated interferon, bexarotene, and combinations with radiotherapy or extracorporeal photopheresis.
The Lancet Haematology published a clinical update in Oncology on 01 Apr 2026.
The item focuses on Patient selection and treatment sequencing in RESMAIN – Author's reply.
Review the original article for the full source wording and details.